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Objectives: Evidence has accrued to suggest that diabetic patients face an increased
risk of ischemic events and low output syndrome and might mount an inordinate
response to ischemia and reperfusion. Because hyperglycemia is a potent stimulus
for endothelin-1 production, we hypothesized that increased production, action, or
both of endothelin-1 in diabetes might represent an important mediator of endothe-
lial dysfunction in patients with that disease. To this aim, we compared the effects
of cardioplegic arrest and reperfusion on coronary sinus effluent endothelin-1 levels
and atrial arteriolar vascular responses in diabetic and case-matched nondiabetic
patients undergoing coronary artery bypass grafting.
Methods: In study 1 coronary sinus effluent endothelin-1 levels were assessed at
baseline and at 1 and 10 minutes after reperfusion in 13 diabetic and 12 nondiabetic
patients matched for age, ejection fraction, Parsonnet score, and crossclamp time. In
study 2 vascular responses of atrial arterioles subjected to perioperative ischemia-
reperfusion were evaluated with videomicroscopy. Atrial microvessels (from ap-
pendages) were obtained before and after removal of the aortic crossclamp, and
vascular responses to exogenously administered endothelin-1 (1010 mol/L) and
substance P (108 mol/L) were studied in the presence or absence of BQ-123, an
endothelin A receptor antagonist.
Results: Diabetic patients elaborated more endothelin-1 at 1 and 10 minutes after
reperfusion (P  .01). Endothelin-1-mediated vasoconstriction was similar in dia-
betic and nondiabetic atrial microvessels before cardioplegic arrest and cardiopul-
monary bypass. After cardiopulmonary bypass and reperfusion, endothelin-1-
mediated vasoconstriction was enhanced in both groups; however, this response was
greater in microvessels from diabetic patients (P  .02). BQ-123, the endothelin A
antagonist, attenuated the effects of bypass and reperfusion on endothelin-1-mediated
vasoconstriction in both groups (P  .01). Substance P-mediated vasodilatation was
similar in diabetic and nondiabetic atrial microvessels before bypass. After bypass and
reperfusion, substance P-mediated vasodilatation was diminished in both groups; how-
ever, this response was more pronounced in the diabetic group (P  .003). BQ-123
coincubation restored substance P-mediated vasodilatation in both groups.
Conclusions: We determined the following: (1) the coronary effluent release of
endothelin-1 is higher in diabetic than in nondiabetic patients after cardiopulmonary
bypass and reperfusion; (2) diabetic coronary microvessels respond to bypass and
reperfusion with greater endothelin-1-mediated vasoconstriction and diminished nitric
oxide-mediated vasodilatation; and (3) these effects are attenuated by endothelin antag-
From the Division of Cardiac Surgery, To-
ronto General Hospital, University of To-
ronto, Toronto, Ontario, Canada,a and the
Division of Cardiac Surgery, Foothills Hos-
pital, University of Calgary, Calgary, Al-
berta, Canada.b
Supported by the Heart and Stroke Foun-
dation of Ontario (R.D.W.), Canadian Dia-
betes Association (R.D.W., V.R., S.V.),
and Physicians Services Incorporated (S.V.,
R.D.W.). S.V. and P.W.M.F. are fellows of
the Canadian Institutes of Health Research
and Heart and Stroke Foundation of Can-
ada. S.V. was the C. Walton Lillehei Forum
Finalist.
Read at the Eighty-first Annual Meeting of
The American Association for Thoracic
Surgery, San Diego, Calif, May 6-9, 2001.
Received for publication May 15, 2001;
revisions requested July 9, 2001; revisions
received Nov 12, 2001; accepted for publi-
cation Nov 13, 2001.
Address for reprints: Richard D. Weisel,
MD, FRCSC, Professor and Chairman, Di-
vision of Cardiac Surgery, The Toronto
General Hospital, EN 14-215, 200 Eliza-
beth St, Toronto, Ontario, M5G 2C4 Can-
ada (E-mail: richard.weisel@uhn.on.ca).
J Thorac Cardiovasc Surg 2002;123:1114-9
Copyright © 2002 by The American Asso-
ciation for Thoracic Surgery
0022-5223/2002 $35.000 12/6/121972
doi:10.1067/mtc.2002.121972
Cardiopulmonary Support and Physiology Verma et al
1114 The Journal of Thoracic and Cardiovascular Surgery ● June 2002
CSP
onism. Endothelin-1 might be an important mediator of ischemia-reperfusion injury in
patients with diabetes. Furthermore, use of endothelin receptor antagonists might be a
novel strategy for improving the resistance of the diabetic heart to cardioplegic arrest
and reperfusion.
Patients with diabetes are at increased risk ofischemic events.1-8 Furthermore, diabetes rep-resents an important risk factor for poor out-comes after coronary revascularization9-13 andan independent predictor of graft occlusion.The diabetic heart elicits an exaggerated re-
sponse to ischemia-reperfusion, with altered neutrophil ad-
hesion, endothelial dysfunction, myocyte contractility, oxi-
dative stress, and myocardial energetics.14-17 Diabetes is an
independent predictor of low output syndrome after coro-
nary artery bypass graft (CABG) surgery.18 Despite the
accumulating evidence that myocardial ischemic injury is
increased in diabetes, few, if any, diabetes-specific inter-
ventions have been investigated to protect the heart from
ischemic injury during CABG surgery.
Endothelin-1 (ET-1) is one of the most potent vasocon-
strictors known and has been implicated in the development
of a number of cardiovascular diseases, including conges-
tive heart failure, pulmonary hypertension, endothelial dys-
function, atherosclerosis, and vasospasm. Because hyper-
glycemia is a potent stimulus of ET-1 production, we
hypothesized that increased production, action, or both of
ET-1 might represent an important mediator of endothelial
dysfunction in diabetes. To this aim, we compared the
effects of cardioplegic arrest and reperfusion on coronary
sinus effluent ET-1 levels and atrial arteriolar vascular re-
sponses in diabetic and case-matched nondiabetic patients
undergoing CABG.
Patients and Methods
Study 1: Coronary Sinus Effluent Production of ET-1
Thirteen patients with type 2 diabetes and 12 nondiabetic patients
undergoing elective CABG surgery were studied. The nondiabetic
patients were case matched for age, ejection fraction, number of
vessels bypassed, Parsonnet score, and crossclamp time (Table 1).
Cardioplegic arrest was achieved by means of cold antegrade
infusion and maintained with intermittent retrograde infusions.
Additional infusions were given after each distal anastomosis was
completed. The preoperative and perioperative management of
patients was similar between groups. A coronary sinus blood
sample was obtained from the retrograde cardioplegia catheter
before the initiation of cardiopulmonary bypass and 1 and 10
minutes after removal of the aortic crossclamp. For determination
of ET-1 levels, plasma samples were acidified with 0.25 mol/L
HCl and then passed through SEP columns. After extraction, the
eluate was analyzed for ET-1 by using a commercial ELISA (R&D
systems). Data are expressed as picograms per milliliter.
Study 2: Vascular Responses of Atrial Microvessels
A segment of right atrial appendage was harvested after systemic
heparinization and before CPB (control) and 15 minutes after
removal of the aortic crossclamp and before administration of
protamine (reperfusion group). Atrial microvessels (range, 150-
250 m) were dissected out (at 4°C) and transferred to an exper-
imental chamber of an arteriograph filled with oxygenated physi-
ologic salt solution (Krebs buffer) and maintained at 37°C (pH
7.4). Each vessel was secured onto a proximal glass microcannula
with a tip diameter of 40 to 80 m and secured with 10-0 sutures.
After several minutes of perfusion, the distal outflow cannula was
closed, and the transmural pressure was slowly increased to 40 mm
Hg by using an electronic pressure Servo System (Living Sys-
tems). The arteriograph with the cannulated pressurized artery was
mounted on the stage of an inverted microscope with a mono-
chrome video camera attached to a viewing tube and was allowed
to equilibrate for 60 minutes. Arterial dimensions were measured
with the video system. Myogenic tone developed spontaneously
(10%-15%) and consistently during equilibration procedures, de-
creasing the luminal diameter. Change in internal diameter was
recorded in response to each intervention. The baseline internal
diameter was determined immediately after cannulation and trans-
fer to the chamber before pressurization or the development of
spontaneous tone (maximal passive diameter). After the vessels
had been allowed to equilibrate (for 30-60 minutes), they were
stimulated with ET-1 (1010 mol/L) in the presence and absence of
BQ-123 (ETA antagonist, 1 mol/L, used 15 minutes before ET-
1). The percentage of reduction in internal diameter (from base-
line) was recorded as the index of ET-1-mediated vasoconstriction.
To examine nitric oxide (NO)-mediated vasorelaxation, we studied
the effects of substance P (108 mol/L) on the percentage of
increase in internal diameter in arteries with internal diameters of
40% to 50% of the baseline value (achieved either spontaneously





(n  12) P value
Age (y) 59.6 7.3 58.1 6.2 .42
LVEF, (%) 39.7 4.8 46.4 5.2 .28
No. of vessels bypassed 3.2 0.8 3.7 0.3 .52
Parsonnet score 9.3 2.2 8.7 2.3 .37
Crossclamp time (min) 84.5 7.3 78.3 13.2 .31
Random glucose (mmol/L) 10.2 2.1 5.9 1.8* .03
Total cholesterol (mmol/L) 5.7 0.4 4.1 0.4* .02
LDL cholesterol (mmol/L) 3.6 0.3 2.2 0.5* .02
LVEF, Left ventricular ejection fraction; LDL, low-density cholesterol.
*Different from diabetic group.
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or with the addition of U46619, a thromboxane analogue). In some
segments we studied the effects of BQ-123 (1 mol/L) on sub-
stance P-induced vasorelaxation. Because ET-1 causes potent and
protracted vasoconstriction, only one concentration of ET-1 was
studied. The responses are reported as the percentage of increase or
decrease in internal diameter (with 100% representing the maximal
baseline diameter before the vessels were pressurized).
Statistical Analysis
Data are presented as means  SEM. Data were compared with
2-way analysis of variance. When the F ratio indicated a significant
effect, differences were specified by using a Newman-Keuls test
for post hoc comparisons.
Results
Patient Demographics
The demographics of the patient population are presented in
Table 1. The groups were similar in terms of age, ejection
fraction, crossclamp time, Parsonnet score, and number of
vessels bypassed. The diabetic group exhibited a higher
random plasma glucose level and hemoglobin A1C when
compared with the nondiabetic group. In addition, the dia-
betic group had higher total cholesterol and low-density
cholesterol and higher preoperative systolic blood pressure
when compared with the control group. All diabetic patients
were receiving oral antihyperglycemic agents, and none
were taking insulin.
Coronary Effluent ET-1
The coronary sinus effluent ET-1 levels at baseline and after
1 and 10 minutes of reperfusion are depicted in Figure 1.
Despite similar ET-1 release at baseline, the diabetic pa-
tients elaborated significantly more ET-1 during the imme-
diate reperfusion phase.
Atrial Microvessel Function
The baseline internal diameter of the atrial microvessels
studied averaged 146  9 m in the diabetic group and
177  14 m in the nondiabetic group (P  .17). At a
pressure of 40 mm Hg, both groups had myogenic tone, as
evidenced by a reduction in the internal diameter, and the
degree of spontaneous constriction was similar between
groups both before and after reperfusion (diabetic group:
15.3%  4% vs nondiabetic group: 12.6%  3%, P  .42).
Figure 2 depicts the effects of ET-1 (1010 mol/L) on the
percentage of decrease in internal diameter in the control
and diabetic groups after cardioplegic arrest. ET-1 evoked
greater vasoconstriction in both groups after reperfusion;
however, this response was greater in microvessels from
diabetic patients. The ETA antagonist BQ-123 attenuated
the exaggerated ET-1-mediated response in both control and
diabetic microvessels (Figure 2).
The vasodilatory responses to substance P, an NO-
mediated vasorelaxant, were examined in arterioles precon-
tracted to a similar internal diameter, which was achieved
with extraluminal U46619 when necessary. The internal
diameter of the precontracted arteries was similar between
groups (diabetic group: 42%  7% vs nondiabetic group:
57%  8%, P  .36). Figure 3 depicts the endothelium-
dependent responses to substance P (108 mol/L). After
reperfusion, substance P-mediated responses were attenu-
ated in both control and diabetic arterioles. Importantly,
diabetic microvessels exhibited significantly greater attenu-
ation in substance P-mediated vasodilatation. Preincubation
with BQ-123 restored substance P-mediated vasorelaxation
to prereperfusion values in both groups studied (Figure 3).
Discussion
Key Observations
The following observations have been made in this study:
(1) the coronary sinus effluent production of ET-1 is higher
in diabetic than in nondiabetic patients after cardioplegic
arrest, CPB, and reperfusion; (2) diabetic coronary mi-
crovessels respond to CPB and reperfusion with greater
ET-1-mediated vasoconstriction and diminished NO-medi-
ated vasodilatation; and (3) these effects were eliminated by
ET antagonism. These data suggest that ET-1 might be an
important mediator of ischemia-reperfusion injury in diabe-
tes. Furthermore, they suggest that antagonism of ET recep-
tors might represent a potential strategy for improving the
resistance of the diabetic heart to ischemic injury during
cardioplegic arrest and reperfusion.
Coronary Sinus Effluent ET-1 Levels
Our data on ET-1 production support recent observations by
Fogelson and associates19 demonstrating higher ET-1 pro-
Figure 1. Plasma ET levels at baseline and after 1 and 10 minutes
of reperfusion (removal of the aortic crossclamp) in diabetic and
case-matched nondiabetic patients. ET-1 levels are similar at
baseline; however, after reperfusion, the coronary sinus effluent
ET-1 release was higher in the diabetic than in the nondiabetic
group. *P  .01 versus the nondiabetic group. MIN R, Minutes of
reperfusion.
Cardiopulmonary Support and Physiology Verma et al
1116 The Journal of Thoracic and Cardiovascular Surgery ● June 2002
CSP
duction in the immediate reperfusion period in diabetic
patients undergoing CABG. A few issues about ET-1 levels
in this study require discussion. First, we did not assess
arterial ET-1 levels, and hence an index of coronary pro-
duction (ie, arterial minus coronary effluent production)
could not be provided. Second, we did not assess coronary
sinus flow; it is possible that diabetic patients had lower
coronary sinus flow after crossclamp removal, which could
explain the higher ET levels. Third, no assessments of ET-1
production were made after discontinuation of CPB, and
hence we are unable to assess the effects of ET-1 during this
period. Fourth, we did not measure NO production. Because
ET-1 and NO appear to work in concert to maintain vascular
tone and reactivity, such an assessment would have pro-
vided a better index of vascular tone. However, recent
studies have demonstrated similar NO release.20
Hyperglycemia is a potent stimulator of ET-1 synthesis
from the endothelium.21-24 Hyperglycemic diabetic patients
might have produced more ET-1 through this mechanism.
The cardiomyocyte might also be a source of ET-1, and our
in vitro data presented in the accompanying article suggest
that hyperglycemia might serve to increase heart cell ET-1
production. Whatever the cellular mechanism, increased
ET-1 production might serve as an important mediator of
generalized endothelial dysfunction, both directly by means
of vasoconstriction and indirectly by means of inhibiting
NO action. In addition to endothelial damage, elegant stud-
ies from Dorman and associates25 have demonstrated that
ET-1 might directly impair cardiomyocyte contractility by
inducing intracellular calcium overload. Hence the observa-
tion that ET-1 levels might be increased in diabetic patients
is an important finding because it demonstrates that, despite
similar intraoperative management, the diabetic patient re-
sponds differently to perioperative ischemia-reperfusion.
Finally, it is important to appreciate that the majority of
ET-1 production from the endothelium is released ablumi-
nally (toward the vascular smooth muscle and cardiomyo-
cyte). Circulating levels represent a spillover of ET-1 and
underestimate true tissue levels. Hence modest differences
in coronary effluent ET-1 production might reflect much
Figure 2. Percentage decrease in internal diameter (vasoconstriction) in response to 1010 mol/L ET-1 and the ETA
antagonist BQ-123. Atrial microvessels were studied in a pressurized fashion by using videomicroscopy before
cardioplegia, and the results 15 minutes after removal of the aortic crossclamp were depicted. ET-1-mediated
vasoconstriction was higher in both diabetic (n  10) and nondiabetic (n  11) microvessels; however, the
vasoconstrictor effects of ET-1 were greater in diabetic arterioles. BQ-123 attenuated the increased constrictor
responses to ET-1 in both control and diabetic groups. **P  .01 versus control group; ##P  .02 versus
control-reperfusion group; #P  .02 versus control and diabetic groups; *P  .03 versus control-reperfusion and
diabetic-reperfusion groups. R, Reperfusion.
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greater tissue ET-1 concentrations in patients with diabetes.
However, differences in tissue levels remain to be deter-
mined.
Microvessel Function
We found that vascular reactivity increased in both control
and diabetic patients; however, the changes were greater in
the diabetic patients. First, after CPB and reperfusion, va-
soconstriction to similar concentrations of ET-1 was greater
in diabetic microvessels compared with that seen in the
nondiabetic control group. To our knowledge, this study is
the first to demonstrate increased ET-1-mediated vasocon-
striction in both control and diabetic patients after cross-
clamp release. Second, NO-mediated vasorelaxation was
impaired in both groups, and the impairment in vasorelax-
ation was greater in the diabetic microvasculature. Exten-
sive studies by Metais and colleagues26 have demonstrated
that cardioplegic arrest and reperfusion impairs endotheli-
um-mediated responses to substance P in nondiabetic pa-
tients, but this is the first study to demonstrate greater
attenuation of vasorelaxation in diabetic patients. Impor-
tantly, ET receptor antagonism with BQ-123 improved vas-
cular responses to ET-1 and substance P in both the diabetic
and nondiabetic groups. These data suggest that increased
sensitivity of the microvasculature to ET-1 occurs in both
nondiabetic and diabetic patients undergoing CABG sur-
gery. However, the diabetic vascular smooth muscle is more
sensitive to the vasoconstrictor mechanisms of ET-1.
There are a few limitations to the atrial microvessel data
presented in this study that should be borne in mind. First,
no ET-1 dose-response curve was conducted. The responses
of atrial microvessels to one concentration of ET-1 were
studied, and hence it is not possible to determine the agonist
sensitivity. Second, we did not assess the differences in
internal diameter between diabetic and nondiabetic patients
at increasing transmural pressures. Because the diabetic
microvasculature might have greater myogenic tone, this
assessment would have been useful. Furthermore, such a
study would facilitate the correlation between wall tension
and transmural pressure and would provide a sensitive index
of alterations in myogenic tone. Finally, it is important to
realize that in addition to ET-1, other factors, such as
cyclooxygenase-derived products, might be important in the
development of vascular dysfunction after CPB and reper-
fusion. Studies from Metais and colleagues26 have demon-
strated that cardioplegic arrest and reperfusion causes en-
hanced serotonin-mediated vasoconstriction through the
release of cyclooxygenase-2-derived products and impaired
NO production. Although there might be an interaction
between other vasoconstrictor products and ET-1, this was
not assessed in the present study.
Conclusions
We determined the following: (1) the coronary effluent
release of ET-1 was higher in diabetic than in nondiabetic
patients after CPB and reperfusion; (2) diabetic coronary
Figure 3. Percentage increase in internal diameter (vasodilatation) in response to 108 mol/L substance P and the
ETA antagonist BQ-123 in arterioles precontracted to 40% to 50% of baseline internal diameter achieved either
spontaneously or with additions of U46619. Substance P-mediated vasodilatation was similar at baseline between
the control and diabetic groups. The results after reperfusion are depicted. Substance P-mediated responses were
attenuated in both the control and diabetic groups, but the relaxation was greater in the diabetic vessels. BQ-123
prevented the decrease in substance P responses in both control and nondiabetic groups. **P .02 versus control,
diabetic, and diabetic-reperfusion groups; #P  .01 versus control, diabetic, and control-reperfusion groups; *P 
.01, versus control-reperfusion and diabetic-reperfusion groups.
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microvessels respond to CPB and reperfusion with greater
ET-1-mediated vasoconstriction and diminished NO-medi-
ated vasodilatation; and (3) these effects were attenuated by
ET antagonism. ET-1 is an important mediator of ischemia-
reperfusion injury in diabetes. Furthermore, our results sug-
gest that antagonism of ET receptors might represent a
novel strategy for improving the resistance of the diabetic
heart to ischemic injury during cardioplegic arrest and after
reperfusion. Given the increasing evidence of a role of ET-1
as a mediator of perioperative injury,27-32 we suggest that a
phase I study be conducted to develop ET receptor antag-
onists for high-risk patients undergoing cardiac operations.
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